Skip to main content

A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus T

Clinical Trial Grant
Duke Scholars

Administered By

Duke Human Vaccine Institute

Awarded By

Moderna Therapeutics, Inc.

Start Date

February 27, 2020

End Date

September 1, 2020
 

Administered By

Duke Human Vaccine Institute

Awarded By

Moderna Therapeutics, Inc.

Start Date

February 27, 2020

End Date

September 1, 2020